MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection
Sarah A E Rupprechter, Derek J Sloan, Wilna Oosthuyzen, Till T Bachmann, Adam T Hill, Kevin Dhaliwal, Kate Templeton, Joshua Matovu, Christine Sekaggya-Wiltshire, James W Dear, Sarah A E Rupprechter, Derek J Sloan, Wilna Oosthuyzen, Till T Bachmann, Adam T Hill, Kevin Dhaliwal, Kate Templeton, Joshua Matovu, Christine Sekaggya-Wiltshire, James W Dear
Abstract
Aims: Patients on antituberculosis (anti-TB) therapy are at risk of drug-induced liver injury (DILI). MicroRNA-122 (miR-122) and cytokeratin-18 (K18) are DILI biomarkers. To explore their utility in this global context, circulating miR-122 and K18 were measured in UK and Ugandan populations on anti-TB therapy for mycobacterial infection.
Methods: Healthy subjects and patients receiving anti-TB therapy were recruited at the Royal Infirmary of Edinburgh, UK (ALISTER-ClinicalTrials.gov Identifier: NCT03211208). African patients with human immunodeficiency virus-TB coinfection were recruited at the Infectious Diseases Institute, Kampala, Uganda (SAEFRIF-NCT03982277). Serial blood samples, demographic and clinical data were collected. In ALISTER samples, MiR-122 was quantified using polymerase chain reaction. In ALISTER and SAEFRIF samples, K18 was quantified by enzyme-linked immunosorbent assay.
Results: The study had 235 participants (healthy volunteers [n = 28]; ALISTER: active TB [n = 30], latent TB [n = 88], nontuberculous mycobacterial infection [n = 25]; SAEFRIF: human immunodeficiency virus-TB coinfection [n = 64]). In the absence of DILI, there was no difference in miR-122 and K18 across the groups. Both miR-122 and K18 correlated with alanine transaminase (ALT) activity (miR-122: R = .52, 95%CI = 0.42-0.61, P < .0001. K18: R =0.42, 95%CI = 0.34-0.49, P < .0001). miR-122 distinguished those patients with ALT>50 U/L with higher sensitivity/specificity than K18. There were 2 DILI cases: baseline ALT, 18 and 28 IU/L, peak ALT 431 and 194 IU/L; baseline K18, 58 and 219 U/L, peak K18 1247 and 3490 U/L; baseline miR-122 4 and 17 fM, peak miR-122 60 and 336 fM, respectively.
Conclusion: In patients treated with anti-TB therapy, miR-122 and K18 correlated with ALT and increased with DILI. Further work should determine their diagnostic and prognostic utility in this global context-of-use.
Keywords: cytokeratin-18; drug-induced liver injury; microRNA-122tuberculosis.
Conflict of interest statement
The authors declare no conflicts of interest.
© 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Figures
References
- World Health Organization (WHO) . WHO TB Report. WHO Library Cataloguing‐in‐Publication Data World. 2019.
- Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: Hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935‐952.
- Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. TubercleElsevier. 1977;59(1):13‐32.
- Ramappa V, Aithal GP. ‘Hepatotoxicity Related to Anti‐tuberculosis Drugs: Mechanisms and Management. J Clin Exp Hepatol. 2013;3(1):37‐49.
- Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven A, Dekhuijzen R. Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review. J Gastroenterol Hepatol. 2008;23(2):192‐202.
- Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid‐induced hepatotoxicity: Then and now. Br J Clin Pharmacol. 2016;81(6):1030‐1036.
- Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. Hepatotoxicity mechanisms of isoniazid: A mini‐review. J Appl Toxicol. 2015;35(12):1427‐1432.
- Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug‐induced liver injury. Clin Pharmacol Ther. 2011;89(6):806‐815.
- Pettersson J, Hindorf U, Persson P, et al. Muscular exercise can cause highly pathological liver function tests in healthy men. Br J Clin Pharmacol. 2008;65(2):253‐259.
- LaDue JS, Wroblewski F. The Significance of the Serum Glutamic Oxalacetic Transaminase Activity Following Acute Myocardial Infarction. Circulation. 1955;11(6):871‐877.
- Senior JR. Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future. Clin Pharmacol Ther. 2012;92(3):332‐339.
- Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. DiabetesAmerican Diabetes Association. 2004;53(10):2623‐2632.
- Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new‐onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C‐reactive protein in the west of Scotland coronary prevention study. DiabetesAmerican Diabetes Association. 2004;53(11):2855‐2860.
- Antoine DJ, Dear JW. How to treat paracetamol overdose and when to do it. Expert Rev Clin PharmacolTaylor & Francis. 2016;9(5):633‐635.
- Wang K, Zhang S, Marzolf B, et al. Circulating microRNAs, potential biomarkers for drug‐induced liver injury. Proc Natl Acad Sci. 2009;106(11):4402‐4407.
- Adebayo D, Mookerjee RP, Jalan R. Mechanistic biomarkers in acute liver injury: Are we there yet? J HepatolEuropean Association for the Study of the Liver. 2012;56(5):1003‐1005.
- Caulín C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol. 1997;138(6):1379‐1394.
- Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen‐induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777‐787.
- Dear JW, Clarke JI, Francis B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3(2):104‐113.
- Vliegenthart AD, Shaffer JM, Clarke JI, et al. Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep. 2015;5(1):1–13.
- Food and Drug Administration Centre for Drug Evaluation and Research . Letter of Support for Drug‐Induced Drug‐Induced Liver Injury (DILI) Biomarker(s). 2016. Available at: (Accessed: 8 October 2018).
- Griffith DE, Aksamit T, Brown‐Elliott BA, et al. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367‐416. 10.1164/rccm.200604-571ST
- Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non‐tuberculous mycobacterial pulmonary disease (NTM‐PD). Thorax. 2017;72(Suppl 2):ii1‐ii64. 10.1136/thoraxjnl-2017-210927
- World Health Organization (WHO) . Guidelines for treatment of drug‐susceptible tuberculosis and patient care. Geneva: WHO press; 2017. 10.1586/17476348.1.1.85
- World Health Organization (WHO) . Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: WHO press; 2018. 10.1056/NEJMcp021045
- Nabisere R, Musaazi J, Denti P, et al. Pharmacokinetics, SAfety/tolerability, and EFficacy of high‐dose RIFampicin in tuberculosis‐HIV co‐infected patients on efavirenz‐ or dolutegravir‐based antiretroviral therapy: Study protocol for an open‐label, phase II clinical trial (SAEFRIF). Trials. 2020;21(1):1‐9.
- Balzano F, Deiana M, Dei Giudici S, et al. MiRNA stability in frozen plasma samples. Molecules. 2015;20(10):19030‐19040.
- Shaughnessy RG, Farrell D, Riepema K, Bakker D, Gordon SV. Analysis of biobanked serum from a mycobacterium avium subsp paratuberculosis bovine infection model confirms the remarkable stability of circulating mirna profiles and defines a bovine serum mirna repertoire. PLoS ONE. 2015;10(12):1‐22.
- Karlen Y., McNair A., Perseguers S., Mazza C., Mermod N. Statistical significance of quantitative PCR. BMC Bioinformatics. 2007;8 (1):131. 10.1186/1471-2105-8-131
- Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real‐time PCR experiments. Clin Chem. 2009;55(4):611‐622.
- Olofsson MH, Ueno T, Pan Y, et al. Cytokeratin‐18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res. 2007;13(11):3198‐3206.
- Cummings J, Ranson M, Butt F, Moore D, Dive C. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol. 2007;60(6):921‐924.
- Bethseda (MD): National Institute of Diabetes and Digestive and Kidney Diseases . LiverTox: Clinical and Research Information on Drug‐Induced Liver Injury [Internet] Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury. [Online]. 2017. Available at:
- Church RJ, Kullak‐Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort. Hepatology (Baltimore, md). 2018;69(2):760‐773.
Source: PubMed